Devonian Health Group Inc.

Description

Devonian Health Group Inc. is a healthcare company specialized in biotechnology to develop pharmaceutical and therapeutical product solutions. Devonian Health Group Inc. is a public company listed on the Toronto Venture Stock Exchange (TSXV), with its common shares trading under the ticker symbol GSD.

The Montréal, Quebec-based biotechnology company has developed – ThykamineTM, a therapeutical drug for the treatment for dermatologic diseases, such as atopic dermatitis, ulcerative colitis, radiodermatitis (radiation dermatitis), and inflammatory acne.

In addition to the pharmaceutical drugs, the company also manufactures and markets cosmetics and personal care products under three distinct categories – pharma quality or physician formula brands, prestige products and mass market products.

The company launched its first derma-cosmetic product line, PurgenesisTM – women anti-aging formulation for skin care, which includes day, eye, and night cream. The company utilizes its proprietary natural active ingredient - R-Spinasome™ to manufacture these skin care products.

The United Kingdom-based LUX Life Magazine recognized PurgenesisTM as the winner for excellent anti-aging treatment solutions. The company’s anti-aging solutions are patent-protected in the major markets throughout Europe, Japan, and North America, including the United States and Canada.

Additionally, the cosmeceutical product line of Devonian Health Group comprises the below sun-care products to protect from harmful radiations:

• Blue light protection cream for indoors

• SPF/IRA/Blue light protection lotion for outdoors

All the therapeutical and cosmeceutical products by Devonian are based on the Supra Molecular Complex Extraction and Stabilization Technology, also called SUPREX that break through the active photosynthesis process performed by plants. The SUPREX technology enables the company to extract, purify, stabilize, and condition molecules, such as organic baby spinach, radicchio and chlorella from green plants, red plants, green algae, bacteria, brown algae, and seaweed for the development of biotechnological drugs.

The company owns a state-of-the-art extraction facility in Canada. It is a fully integrated facility with customized equipment.

In February 2018, the company acquired Altius Healthcare Inc. to expand and diversify its commercial operations and exploit market opportunities to match the growth potential in the biotechnological pharmaceutical industry.